Attached files

file filename
EX-10.1 - EXHIBIT 10.1 - Sonnet BioTherapeutics Holdings, Inc.v357710_ex10-1.htm
EX-10.2 - EXHIBIT 10.2 - Sonnet BioTherapeutics Holdings, Inc.v357710_ex10-2.htm
EX-99.1 - EXHIBIT 99.1 - Sonnet BioTherapeutics Holdings, Inc.v357710_ex99-1.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): October 17, 2013

 

CHANTICLEER HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

  

Delaware   000-29507   20-2932652
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification)

 

11220 Elm Lane, Suite 203, Charlotte, NC 28277
(Address of principal executive office) (zip code)
 
 
(Former address of principal executive offices) (zip code)

 

(704) 366-5122
(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))

 

 
 

 

ITEM 1.01Entry Into a Material Definitive Agreement

 

ITEM 3.02Unregistered Sales of Equity Securities

 

On October 17, 2013, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with 12 investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 240,000 Units (the “Units”) at a purchase price of $3.75 per Unit (“Unit Price”), closing a maximum $2,500,000 private placement (the “Private Placement”). The aggregate purchase price we received from the sale of the 240,000 Units was $900,000. Each Unit consists of (a) one (1) share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (b) one (1) five (5) year warrant, exercisable after twelve (12) months, to purchase one (1) share of common stock at an initial exercise price of five dollars ($5.00) (the “Warrants”). The Private Placement offered a total of 666,667 Units, with 426,667 Units at an “all or none basis” and 240,000 Units available at a “best efforts basis.” The purchase of the 426,667 Units at “all or none basis” was closed on October 7, 2013.

 

The Units include registration rights requiring the Company to cause the shares of Common Stock and the shares of Common Stock underlying the Warrants to be included in a registration statement that shall be filed no later than December 31, 2013 and declared effective no later than April 30, 2014.

 

The Company employed a placement agent for the purpose of the Private Placement, and has paid to the Placement Agent commissions in the total amount of $150,000 and five (5) year warrants convertible into an aggregate of 40,000 shares.

 

The Units we agreed to issue in the foregoing transaction and the Securities contained therein were not and will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

 

The Units offered and sold in connection with the closing of this Private Placement were in reliance on Section 4(2) of the Securities Act of 1933 (the “Securities Act”) or Rule 506 of Regulation D promulgated thereunder. In connection with this Private Placement, we relied on the Investors’ written representations, including a representation that the Investor is an “accredited investor” as that term is defined in Rule 501(a) under the Securities Act. The Investors also represented that they were acquiring the Units for investment only and not with a view towards resale or distribution. We requested our stock transfer agent to affix appropriate restrictive legends to the stock certificates issued to the Investors. The Investors were given adequate access to sufficient information about the Company to make an informed investment decision. Neither the Company nor anyone acting on its behalf offered or sold these Units by any form of general solicitation or general advertising.

 

 
 

 

A copy of the Subscription Agreement and Warrant has been attached as Exhibits 10.1 and 10.2, respectively, to this current report on Form 8-K to provide our shareholders and investors with information regarding their terms. It is not intended to provide any other factual information about the Company or any of their respective affiliates or businesses.

 

ITEM 9.01.Financial Statements and Exhibits.

 

(d)Exhibits

 

10.1Form Subscription Agreement*

 

10.2Form Common Stock Warrant*

 

99.1Press release dated October 21, 2013.

 

*Previously filed in the Company’s Form 8-K filed October 10, 2013

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:               October 21, 2013

 

    Chanticleer Holdings, Inc.
       
    By: /s/  Michael D. Pruitt
      Michael D. Pruitt
      Chief Executive Officer

 

 
 

 

EXHIBIT INDEX

 

Exhibit No.   Description   Manner of Filing
10.   Form Agreements   Furnished Electronically
99.1   Press Release dated Oct. 21, 2013   Furnished Electronically